Last 4,475 KRW
Change Today -60.00 / -1.32%
Volume 286.6K
002210 On Other Exchanges
Symbol
Exchange
Korea SE
As of 1:15 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

dongsung pharmaceutical co (002210) Snapshot

Open
4,550
Previous Close
4,535
Day High
4,625
Day Low
4,460
52 Week High
09/2/14 - 9,320
52 Week Low
08/1/14 - 3,455
Market Cap
97.4B
Average Volume 10 Days
493.0K
EPS TTM
96.00
Shares Outstanding
21.8M
EX-Date
12/27/13
P/E TM
46.6x
Dividend
30.00
Dividend Yield
0.67%
Current Stock Chart for DONGSUNG PHARMACEUTICAL CO (002210)

Related News

No related news articles were found.

dongsung pharmaceutical co (002210) Related Businessweek News

No Related Businessweek News Found

dongsung pharmaceutical co (002210) Details

Dongsung Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products primarily in South Korea. The company offers medicines, including antirheumatics and anti-inflammatory analgesics, anti-inflammatory enzymes, cardiovascular system drugs, gastrointestinal drugs, antispasmodic agents, respiratory agents, anti-histamines, dermatologicals, antibiotics, antidiarrheals, antifungals, oral hypoglycemic agents, hormones, hypnotics and sedatives, minor tranquillizers, and other medicines. It also provides products for digestive system and respiratory system; hair dyes; and cosmetics. The company exports its hair dyes to China, Malaysia, Singapore, and Thailand. It has an agreement with Bentley Pharmaceuticals to develop an intranasal insulin spray formulation. The company was founded in 1957 and is based in Seoul, South Korea.

298 Employees
Last Reported Date: 08/14/13
Founded in 1957

dongsung pharmaceutical co (002210) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

dongsung pharmaceutical co (002210) Key Developments

BioGaia AB Signs Exclusive Distribution Agreement with Dongsung Pharmaceutical Co. Ltd

BioGaia AB has signed an agreement with Dongsung Pharmaceutical Co. Ltd., for the exclusive rights to sell BioGaia's ProTectis baby drops and ProTectis and Gastrus tablets through the retail pharmacy channel in South Korea from 2013. The products will be sold under BioGaia's own brand. The partnership with Dong Sung will significantly improve BioGaia's existing distribution coverage in South Korea with sales through the retail pharmacy channel. BioGaia's existing partner will continue covering the multi-level marketing channel.

Dongsung Pharmaceutical Co. Ltd., Annual General Meeting, Mar 22, 2013

Dongsung Pharmaceutical Co. Ltd., Annual General Meeting, Mar 22, 2013., at 10:00 Korea Standard Time. Location: Seoul and Dobong 683 Province Pharmaceutical Building B1F. Agenda: To approve Article 56 financial statement; to approve directors' remuneration limit; and to approve audit fees limit.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002210:KS 4,475.00 KRW -60.00

002210 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002210.
View Industry Companies
 

Industry Analysis

002210

Industry Average

Valuation 002210 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DONGSUNG PHARMACEUTICAL CO, please visit www.dongsung-pharm.co.kr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.